News & Events zu Galmed Pharmaceuticals Ltd (GLMD)GLMDGalmed Pharmaceuticals Ltd

Galmed Advances Aramchol for Parkinson's Disease Treatment

Galmed announced continued advancement of Aramchol as a potential disease-modifying therapy for Parkinson's disease, or PD, reporting significant progress in development of new Aramchol orally dispersible film - ODF - formulation. The data demonstrate ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral administration. In addition to enhancing CNS drug delivery, Aramchol's proprietary ODF formulation directly addresses one of the most common clinical challenges in Parkinson's. Up to 80% of patients develop dysphagia during disease progression, making conventional tablets and liquid formulations increasingly difficult to swallow and contributing to poor treatment adherence. Aramchol's rapidly dissolving ODF formulation dissolves within seconds without water, eliminates the need to swallow conventional tablets or liquids, thus simplifying administration and possibly improving long-term treatment adherence. Unlike currently approved therapies that primarily improve motor symptoms through dopaminergic replacement, Aramchol targets SCD1-related biological mechanisms associated with disease progression. Galmed's in-vitro data demonstrated that Aramchol dose-dependently down-regulated alphaSyn aggregation as well as indicating that the effect was not associated with toxicity. Galmed's ODF formulation of Aramchol represents a dual innovation: a mechanism-based approach to slowing disease progression combined with drug delivery that addresses dysphagia affecting Parkinson's patients.

Galmed and Barcode Nanotech Develop New Aramchol-based LNP for Cardiac Delivery

Galmed announced the breakthrough development of a new Aramchol-based lipid nanoparticles formulation, or LNP, for targeted delivery to the heart. The development work, a collaboration between Galmed and Barcode Nanotech, applies advanced formulation science, in vivo screening, and AI-enabled analysis which aims to identify optimal vehicles for precise cardiac delivery. The platform enables in vivo screening of hundreds of nanoparticle candidates to support the identification of formulations with potentially improved targeting, biodistribution, and functional performance. By adapting this platform to cardiac applications, the companies aim to develop cardiac-targeted therapies delivered through LNPs that can selectively engage relevant cell populations, including fibroblasts and other disease-driving cardiac cells.